ArticleEuropean journal of nuclear medicine and molecular imaging2026
Characteristics of [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IDH-Mutant Diffuse Glioma: From Metabolic Origins to Targeted Therapy.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAmino acid positron emission tomography (PET) is increasingly utilized in the clinical workup of patients with glioma. To better understand the PET characteristics of IDH-mutant glioma according to the 2021 WHO classification of CNS tumours, this retrospective study explored the association between amino acid PET and magnetic resonance imaging (MRI) characteristics in patients with newly diagnosed IDH-mutant glioma.
methodsPatients with histologically verified IDH-mutant glioma who underwent [18F]FET PET/CT scans without prior treatment were included. PET parameters (PET-positivity according to PET RANO 1.0 criteria, maximal and mean tumour-to-background ratio (TBRmax, TBRmean), PET volume and uptake kinetics including minimal time-to-peak (TTPmin)) were assessed and compared with neuropathological findings and contrast-enhanced MRI including Dice similarity coefficients for spatial overlap between PET and MR signals.
resultsA total of 147 patients were included (79 astrocytomas, 68 oligodendrogliomas). Contrast enhancement was present in 44/147 tumours (29.9%), most frequently in astrocytoma WHO grade 4 (8/9, 88.9%). [¹⁸F]FET PET was positive in 62/68 oligodendrogliomas (91.2%) and 35/79 astrocytomas (44.3%), with significantly higher uptake intensities in oligodendrogliomas (median TBRmax 2.43 vs. 1.55; p < 0.001) and increasing values with WHO grade. PET–CE spatial overlap was generally low (median Dice 0.26 (range: 0.01–0.90)), whereas PET–FLAIR overlap was higher (median Dice 0.55 (range: 0.05–0.99)) and showed significant differences between histologies and grades. Dynamic [¹⁸F]FET PET data were available in 91/147 tumours (61.9%) and demonstrated predominantly increasing kinetics (61.5%). In the TTPmin analysis, WHO grade 4 astrocytomas clustered in the early 12.5-min group, whereas WHO grade 2–3 gliomas showed later peaks (17.5–35 min).
conclusion[18F]FET PET uptake intensity correlates positively with the CNS WHO grade in IDH-mutant gliomas, but with marked overlap between tumour grades, and provides complementary information to contrast-enhanced MRI. [18F]FET PET may therefore add another layer of information on tumour characteristics and should be further investigated as a complementary biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.